Recent Updates
Recently added Catalysts

-darigabat

Phase 1

Healthy Participants | Small molecule | Other |AbbVie Inc.|Last Updated: Jul 30, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials2
Total Enrollment21
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06435923A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male ParticipantsPHASE1 COMPLETED 8May 1, 2024Jul 1, 2024Jul 30, 2024 -
NCT05824143Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult ParticipantsPHASE1 COMPLETED 13Apr 1, 2023Jul 1, 2023Aug 2, 2023 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
[14C]-darigabatDRUGOral capsule
DarigabatDRUGOral tablet
CarbamazepineDRUGOral tablets
Unlock Study Design Details